Natera, Inc.

Natera, Inc.

Natera, Inc.

Overview
Date Founded

2007

Headquarters

201 INDUSTRIAL ROAD, SUITE 410, SAN CARLOS, CA, 94070

Type of Company

Public

Employees (Worldwide)

975

Industries

Medical Support Services
IT Consulting & Services
Biotechnology

Company Description

Natera, Inc. engages in the discovery, development, and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test, Horizon Carrier Screening, Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis, Anora Products of Conception and Non-Invasive Paternity Testing. The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in San Carlos, CA.

Contact Data
Trying to get in touch with decision makers at Natera, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Co-Founder

Co-Founder

President, Chief Executive Officer & Director

Chief Financial Officer & Chief Accounting Officer

Chief Operating Officer

Secretary & General Counsel

Chief Medical Officer & Senior Vice President, Medical Affairs

General Manager, Oncology & Transplant

General Manager, Women's Health

Senior Director, Clinical Genetic Services

Board of Directors

Co-Founder at Natera, Inc.

Partner at Sequoia Capital

Chief Medical Officer at Merck & Co., Inc.

Former Chief Financial Officer & Head-Investor Relations at Natera, Inc.

Co-Founder at Natera, Inc.

President at Sofinnova Ventures, Inc.

Co-Founder & Managing Partner at Leerink Transformation Partners LLC

President, Chief Executive Officer & Director at Natera, Inc.

Head of Johnson & Johnson Innovation California at Johnson & Johnson

Director-Global Healthcare Management at Massachusetts College of Pharmacy and Allied Health Sciences

Paths to Natera, Inc.
Potential Connections via
Relationship Science
You
Natera, Inc.
Owners & Shareholders
Details Hidden

OrbiMed Advisors focuses on investments in the global healthcare industry. They utilizes strategies based on evaluating pharmaceutical, biotechnology, medical device, healthcare services and other companies in the global healthcare sector. The instruments in which OrbiMed invests include US and non-US equities, both long and short, as well as privately placed securities, debt securities, royalty bonds and other royalty instruments, currencies, private investments in public equity securities (PIPEs), ETFs, index options, and derivatives (including swap agreements). The firm invests across the global healthcare industry, from seed-stage venture capital to large publicly-traded companies. Investments are made across three strategies: public equity, private equity, and royalty opportunities. OrbiMed Advisors manages a series of public equity funds, including long/short event-driven funds and closed-end investment trusts. They invest across all types of publicly-traded companies, from biopharmaceuticals to medical devices and healthcare services worldwide. OrbiMed's private equity strategy is broad and flexible, investing from start-ups through growth equity. OrbiMed is typically a lead investor, seeking to help build our portfolio companies. Their geographic focus includes North America, Asia, Europe and Israel. For Royal Opportunities strategy, OrbiMed provides commercial-stage healthcare companies with non-dilutive structured debt capital. Additionally, they can monetize royalty streams, providing valuable financing solutions to owners of intellectual property.

Details Hidden

Deerfield Management Co. focuses on investments in growth stocks across the healthcare sector. They target companies with sound fundamentals, long-term earnings growth potential and the potential to capitalize on market trends. Deerfield's approach is based on extensive fundamental research into healthcare sector assets and investment opportunities. They invest mainly in US companies or companies that issue securities available in US public markets. Although this is their focus, there is no geographic limitation on investments and Deerfield may invest outside the US when situations warrant. Their funds generally pursue one of 3 strategies: Large-Cap, Special Situations and Private Design.Deerfield's Large-Cap strategy invests mainly in debt and equity securities, including exchange traded derivative securities, of publicly-traded companies in the healthcare sector. The strategy seeks capital appreciation through a combination of security selection based on fundamental analysis, diversification through investments in stock, debt and derivatives and a mix of long and short positions.The firm's Special Situations strategy emphasizes investments in publicly traded healthcare companies with smaller market-caps. At least 90% of investments must in healthcare companies, and essentially all investments are healthcare related. Investments include equity, debt, royalties or other assets, some of which may have limited liquidity. The strategy makes both long and short investments and may utilize leverage.Deerfield's Private Design strategy invests in public and private healthcare companies using privately created instruments, structures and transactions. This may include, but is not limited to, joint ventures, project financing, contracting for revenue streams, purchasing products/services outright (including intellectual property), participating in LBOs, restructurings and outright buyouts, and developing/participating in the development and sale of therapeutics, medical devices and healthcare products/services.

Details Hidden

Driehaus Capital Management LLC (the "Firm") is a privately-held, independent investment adviser based in Chicago, Illinois and also has an office in New York, New York. Driehaus has been a registered investment adviser with the U.S. Securities and Exchange Commission since March 11, 1983. With approximately $9.07 billion in assets under management, the Firm manages domestic, global, ex-U.S. and dedicated emerging markets equity investment strategies as well as long/short credit investment strategies. We have a global institutional investor base that includes corporate pensions, public funds, endowments, foundations, sub-advisory mandates, financial advisers and family offices. Our niche is that of a smaller, performance-oriented investment adviser with the resources of a much larger organization.

Recent Transactions
Details Hidden

CBR Systems, Inc., California Cryobank LLC purchase Natera, Inc. /Evercord from Natera, Inc.

Details Hidden

Natera, Inc. issued USD Common Stock

Details Hidden

Natera, Inc. issued USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Underwriter

Advised onNatera, Inc. issued Common Stock

Escrow Agent

Advised onNatera, Inc. issued Common Stock

Underwriter

Advised onNatera, Inc. issued USD Common Stock

Associate

Advised onNatera, Inc. issued USD Common Stock

Legal Advisor

Advised onNatera, Inc. issued USD Common Stock

Associate

Advised onNatera, Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Partner at Davis Polk & Wardwell LLP

Legal Advisor

Former Attorney at Davis Polk & Wardwell LLP

Publicist

Professional at Sullivan & Associates

Clients

Yale-New Haven Health Services Corp. operates as a non-profit organization that provides healthcare services. It offers geriatrics, oncology, neurology and neurosurgery, orthopedics, primary care, transplantation, clinical programs and services, health education, and research and clinical trials. The company was founded in 1995 and is headquartered in New Haven, CT.

Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions; Analytical Instruments; Specialty Diagnostics; and Laboratory Products and Services. The Life Sciences Solutions segment comprises of portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs, and vaccines as well as diagnosis of disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment gives diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment involves in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.

BGI Genomics Co., Ltd. is a holding company that engages in development of science and technology services in genomics field. Its business scope ranges from scientific, health, agricultural and informatics. The company was founded by Wang Jian on September 9, 1999 and is headquartered in Shenzhen, China.

Key Stats and Financials As of 2018
Market Capitalization
$2.6B
Total Enterprise Value
$773M
Earnings Per Share
$-2.22
Revenue
$258M
EBITDAMargin
-40.98%
Net Profit
$-128M
EBITDA
$-106M
Total Equity
$32.2M
Total Debt
$124M
Enterprise Value Sales
3x
Debt TEV
0.16x
TEVNet Income
-6.03x
Three Year Compounded Annual Growth Rate Of Revenue
10.39%
Five Year Compounded Annual Growth Rate Of Revenue
36.1%
Investors
Details Hidden

Claremont Creek Partners (CCP) invests in early-stage information technology companies. The firm is particularly interested in the following areas: (1) mobility including voice, data and converging platforms that facilitate collaboration in non-hierarchical, widely distributed organizations (2) healthcare including research and clinical information technology applications such as instrumentation, patient management systems and bio-informatics (3) energy efficiency including capital efficient technologies that relate to energy efficiency retrofits, monitoring and controls and platforms that improve the delivery of energy-related services and (4) security including both the digital and physical systems that comprise mobile, small business and enterprise computing environment. CCP is also interested in investments in other developing areas including VoIP, alternative energy, payment processing and distributive workforce collaboration. The firm places special emphasis on opportunities located beyond Silicon Valley. They invest in early-stage companies that have typically already received angel funding but have not yet participated in a traditional first round of venture finance. Investments generally range from $500,000 to $3 million with the potential for follow-on investments.

Details Hidden

Harmony Partners is a bi-coastal boutique venture capital firm whose mission is to enable software entrepreneurs to optimize expansion stage financings. With offices in New York City and Silicon Valley, Harmony fills a gap in the market for entrepreneur-friendly expansion stage capital. Harmony eliminates the deal constraints of traditional growth equity firms: $30-50 million minimum check sizes, >20% ownership targets, mandatory board seats, vetoes on M&A events, and multi-layered decision making. As such, the firm works collaboratively with Founders to craft the ideal financing that minimizes dilution, saves the company time and effort, while accommodating insider appetite and making room for strategics if relevant. Harmony has a longer-term orientation than most funds because the majority of its capital comes from seven billionaire family offices, and as result, the firm looks to buy in the IPO, not sell. Since 1993, the founding partners have invested in over 80 technology-driven companies including Anaplan, AppDynamics, Aveksa, ComScore, Coremetrics, E*Trade, Intersect ENT, Natera, Predictive Systems, Postmates, Priceline, Peribit, Scopus, Spotify, SS&C, Xactly, and Zerto. To learn more, please visit www.harmonyvp.com.

Details Hidden

OrbiMed Advisors focuses on investments in the global healthcare industry. They utilizes strategies based on evaluating pharmaceutical, biotechnology, medical device, healthcare services and other companies in the global healthcare sector. The instruments in which OrbiMed invests include US and non-US equities, both long and short, as well as privately placed securities, debt securities, royalty bonds and other royalty instruments, currencies, private investments in public equity securities (PIPEs), ETFs, index options, and derivatives (including swap agreements). The firm invests across the global healthcare industry, from seed-stage venture capital to large publicly-traded companies. Investments are made across three strategies: public equity, private equity, and royalty opportunities. OrbiMed Advisors manages a series of public equity funds, including long/short event-driven funds and closed-end investment trusts. They invest across all types of publicly-traded companies, from biopharmaceuticals to medical devices and healthcare services worldwide. OrbiMed's private equity strategy is broad and flexible, investing from start-ups through growth equity. OrbiMed is typically a lead investor, seeking to help build our portfolio companies. Their geographic focus includes North America, Asia, Europe and Israel. For Royal Opportunities strategy, OrbiMed provides commercial-stage healthcare companies with non-dilutive structured debt capital. Additionally, they can monetize royalty streams, providing valuable financing solutions to owners of intellectual property.

Suppliers
Illumina, Inc. Computer Software | SAN DIEGO, CA

Illumina, Inc. engages in the development and manufacture of integrated systems for the analysis of genetic variation and function. It operates through the Core Illumina and Consolidated Variable Interest Entity segments (VIE). The Core Illumina segments serve customers in the research, clinical and applied markets, and enable the adoption of genomic solutions. The Consolidated VIE segment includes activities of GRAIL and Helix. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Streck, Inc. Biotechnology | Omaha, NE

Streck, Inc. manufactures hematology, chemistry, and immunology products for the clinical laboratory. It offers technical and customer support services, pipet verification, and statistics. The company was founded by Wayne Ryan in 1971 and is headquartered in Omaha, NE.

DNAnexus, Inc. Computer Software | Mountain View, CA

DNAnexus, Inc. develops a cloud-based data analysis and management platform for DNA sequence data. It engages in the provision of cloud-based solutions for large-scale Deoxyribonucleic acid (DNA) data management and analysis. The firm offers a centralized hub for managing data, collaborating with other scientists, sharing tools, and accessing diverse reference datasets, including genotypic and phenotypic data. The company was founded by Serafim Batzoglou, Andreas Sundquist and Arend Sidow in 2009 and is headquartered in Mountain View, CA.

Competitors
OPKO Health, Inc. Pharmaceuticals - MIAMI, FL

OPKO Health, Inc. engages in the provision of healthcare services. It operates through the Diagnostics and Pharmaceuticals segments. The Diagnostics segment comprises clinical laboratory operations which acquired through the Bio-Reference and point-of-care operations. The Pharmaceuticals segment includes the pharmaceutical operations acquired in Chile, Mexico, Ireland, Israel, and Spain; and pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.

Genomic Health, Inc. Medical Support Services - Redwood City, CA

Genomic Health, a global health company founded in August of 2000 and located in Redwood City, California, is committed to improving the quality of cancer treatment decisions through the research, development and commercialization of genomic-based clinical laboratory services. To that end, the company conducts sophisticated genomic research to develop clinically-validated molecular diagnostics which provide individualized information on response to certain types of therapy, as well as the likelihood of disease recurrence. These diagnostic technologies generate information that healthcare providers and patients can use in making treatment decisions. At Genomic Health, we developed and follow a highly specialized process that not only adheres rigorously to CAP (College of American Pathologists) standards and CLIA (Clinical Laboratory Improvement Amendments) regulations, but also incorporates numerous real-time quality checks and periodic proficiency testing designed to produce a high level of accuracy in information that we deliver to physicians and patients.

Laboratory Corporation of America Holdings Medical Support Services - Burlington, NC

LabCorp provides leading-edge medical laboratory tests and services through a national network of primary clinical laboratories and specialized Centers of Excellence. Recognized for our innovation, quality, and customer convenience, LabCorp delivers timely, accurate results for improved patient care. With scientific expertise in esoteric testing, genomics, and clinical and anatomic pathology, LabCorp performs more than 1 million tests on more than 370,000 specimens each day. LabCorp is a pioneer in applying advances in medicine and science to laboratory testing, with more than 35 years of experience in serving physicians and their patients. LabCorp operates a sophisticated laboratory network, with corporate headquarters in Burlington, NC, and more than 30,000 employees nationwide. Our 220,000 clients include physician offices, hospitals, managed care organizations, and biotechnology and pharmaceutical companies. Laboratory Corporation of America Holdings is listed on the New York Stock Exchange (NYSE) under ticker symbol LH

Awards & Honors
2014
World Economic Forum - Technology Pioneers
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Natera, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Natera, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Natera, Inc..